Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.46 TRY | +2.71% |
|
-0.92% | -26.20% |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.20% | 845M | D- | ||
+26.00% | 75.67B | C+ | ||
+11.84% | 8.62B | B | ||
+1.22% | 8.29B | C | ||
-36.37% | 6.6B | B- | ||
+19.60% | 5.45B | B- | ||
+2.20% | 4.1B | B | ||
-9.97% | 3.76B | B- | ||
-11.12% | 3.3B | B+ | ||
+9.19% | 3.22B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SELEC Stock
- Ratings Selçuk Ecza Deposu Ticaret ve Sanayi